Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab.

ABSTRACT:

Importance

Ustekinumab, a monoclonal antibody targeting interleukin 12/23p40 (IL-12/23p40), is effective in the treatment of moderate to severe psoriasis, psoriatic arthritis, and Crohn disease. In 2011, a meta-analysis of randomized clinical trials reported a potential risk of severe cardiovascular events (SCEs) within the first few months after the initiation of anti-IL-12/23p40 antibodies.

Objective

To assess whether the initiation of ustekinumab treatment is associated with increased risk of SCEs.

Design, setting, and participants

This case-time-control study used data from the French national health insurance database, covering 66 million individuals, on all patients exposed to ustekinumab between April 1, 2010, and December 31, 2016, classified according to thei

SUBMITTER: Poizeau F 

PROVIDER: S-EPMC7489429 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature